{"id":"msb11456","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MSB11456 is a proposed biosimilar to trastuzumab (Herceptin), a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2) on cancer cells. By blocking HER2 signaling, it inhibits cell proliferation and promotes antibody-dependent cellular cytotoxicity (ADCC) in HER2-overexpressing tumors. As a biosimilar, it is designed to have comparable efficacy and safety to the reference trastuzumab product.","oneSentence":"MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:14.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer"},{"name":"HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT04512001","phase":"PHASE3","title":"MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2020-08-03","conditions":"Rheumatoid Arthritis","enrollment":604},{"nctId":"NCT03282851","phase":"PHASE1","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-11-27","conditions":"Healthy","enrollment":696}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MSB11456","genericName":"MSB11456","companyName":"Fresenius Kabi SwissBioSim GmbH","companyId":"fresenius-kabi-swissbiosim-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling. Used for HER2-positive breast cancer, HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}